CD274 and diffuse large B-cell lymphoma: Although the monotherapy of PD-1/PD-L1 inhibitors is not adequate, the potential combination of PD-1/PD-L1 inhibitors with other therapies may be an effective approach to treat R/R DLBCL patients [70,71].